Heterocyclic compounds useful as inhibitors of tyrosine kinases

Details Heterocyclic compounds useful as inhibitors of tyrosine kinases Heterocyclic compounds useful as inhibitors of tyrosine kinases

2005-01-18

2005-01-18

Rao, Deepak (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Four or more ring nitrogens in the bicyclo ring system

C544S251000, C548S304700, C548S307400

Reexamination Certificate

active

06844435

ABSTRACT:
Disclosed are novel compounds of formula (I):wherein Ar1, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are pharmaceutical compositions comprising these compounds, processes for preparing these compounds and novel intermediate compounds useful in these processes.

REFERENCES:
patent: 4176184 (1979-11-01), Austel et al.
patent: 5646153 (1997-07-01), Spada et al.
patent: 0 322 746 (1989-07-01), None
patent: 459136 (1991-12-01), None
patent: WO 9828281 (1998-07-01), None
patent: WO 9854157 (1998-12-01), None
patent: WO 9924035 (1999-05-01), None
Padmanabha, et al; “1-Methoxy-Agroclavine from Penicillium SP, WC 75209, A Novel Inhibitor of the LCK Tyrosine Kinase”, Bioorganic & Medicinal Chemistry Letters 8 (1998) 569-574.
Faltynek, et al; “Inhibition of T Lymphocyte Activation by a Novel p56lck Tyrosine Kinase Inhibitor”; J. Enzyme Inhibition, 1995, vol. 9, pp. 111-122.
Hanke, et al, “Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor”; Journal of Biological Chemistry, vol. 271, No. 2, 695-701, 1996.
Bullington, et al; “The Development of Novel and Selective p56lck Tyrosine Kinase Inhibitors1”; Bioorganic & Medicinal Chemistry Letters 8 (1998) 2489-2494.
Showalter, et al; “Small Molecule Inhibitors of the Platelet-Derived Growth Factor Receptor, the Fibroblast Growth Factor Receptor, and Src Family Tyrosine Kinases”; Pharmacol. Ther., vol. 76, Nos. 1-3, pp. 55-71, 1997.
Traxler; “Protein tyrosine kinase inhibitors in cancer treatment”; Exp. Opin. Ther. Patents, 1997, 7(6); 571-588.
Traxler; “Tyrosine kinase inhibitors in cancer treatment (Part II)”; Exp. Opin. Ther. Patents, 1998, 8(12); 1599-1625.
Schneller, et al; “Linear and Proximal Benzo-Separated Alkylated Xanthines as Adenosine-Receptor Antagonists”; J. Med. Chem.; 1989, 32, 2247-2254.
Kumar, et al;“Possible Anthelmintic Agents: Syntheses of Various Imidazoquinazolinone Carbamates”; Indian J. Chem., 1981, vol. 20B, 1068-1071.
Agarwal, et al “Segregation of Activity Profile in Benzimidazoles: Effect of Spacers at 5(6)-Position of Methyl Benzimidazole-2-carbamates[1]”; Z. Naturforsch. 48c, 1993, 829-838.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1004-1010, 1996.

Affiliated with

Also associated with

Rating

Heterocyclic compounds useful as inhibitors of tyrosine kinases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclic compounds useful as inhibitors of tyrosine kinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds useful as inhibitors of tyrosine kinases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3407868